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ABSTRACT
Background: The need for muscle relaxants in general anesthesia in different surgeries 
including cardiac surgeries, and the type of relaxant to be used considering its different 
hemodynamic effects on patients with heart disease can be of considerable importance. 
In this study, the hemodynamic effects of two muscle relaxants, Cisatracurium and Atracu-
rium in patients whit low function of left ventricle who are candidate for open heart surgery 
have been considered. Method: This study has been designed as a randomized prospec-
tive double-blind clinical trial. The target population included all adult patients with heart 
disease whose ejection fraction reported by echocardiography or cardiac catheterization 
was 35% or less before the surgery, and were candidate for open heart surgery in Shahid 
Rajaei Heart Center. Taking into account the inclusion and exclusion criteria, the patients 
were randomly placed in two groups of 30 people each. In the induction stage, all the pa-
tients received midazolam, etomidate, and one of the considered muscle relaxant, either 
0.2 mg/kg of cisatracurium or 0.5mg/kg of Atracurium within one minute. In the main-
tenance stage of anesthesia, the patients were administered by infusion of midazolam, 
sufentanil and the same muscle relaxant used in the induction stage. The hemodynamic 
indexes were recorded and evaluated in different stages of anesthesia and surgery as well 
as prior to transfer to ICU. Results: In regard with descriptive indexes (age and sex distri-
butions, premedication with cardiac drugs, ejection fraction before surgery, basic disease) 
there was no statistically significant difference between the groups. Conclusions: The sig-
nificant difference of hemodynamic indexes between the two groups of this study, and the 
need for hemodynamic stability in all stages of surgery for patients with low function of left 
ventricle who are candidate for open heart surgery, proves that administering Cisatracuri-
um as the muscle relaxant is advantageous and better.
Key words: muscle relaxant, Atracurium, Cisatracurium, low function of left ventricle, 
open heart surgery.
1. INTRODUCTION
There is a need for muscle relax-
ants in general anesthesia in differ-
ent surgeries including cardiac sur-
geries, and the type of relaxant to 
be used considering their different 
hemodynamic effects on patients 
with heart disease can be of high 
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importance (1) in a way that the importance of adminis-
tering muscle relaxants as a necessary drug in surgeries 
was suggested in 1942 (2, 3). The muscle relaxants can 
cause hemodynamic changes through releasing hista-
mine, ganglion block, antimauscarine effects on heart, or 
sympathomimetic action. Atracurium which is a muscle 
relaxant in the category of non-depolarizing relaxants 
belonging to benzy1 isoquinolinum group of drugs, has 
been attractive option because of independence of its 
metabolism to main body organs such as liver and kid-
ney, especially in patients with hepatic and renal disease. 
In the meantime, the hemodynamic changes resulting 
from release of histamine after administering Atracu-
rium can be a problem especially in cardiovascular pa-
tients (4, 5). Cisatracurium, an isomer of Atrucium, will 
be metabolized like Atracurium through Hoffman mech-
anism, but contrary to Atracurium, ester hydrolysis has 
no role in its metabolism (6, 7). When a patient is given 
a histamine releaser drug, the clinical signs of elevated 
histamine concentration such as hypotension, tachycar-
dia, head and face erythema will be seen once the plasma 
concentration is increased by2-3 times its initial level, 
and the severity of these clinical signs depends on the 
dose and speed of administration (8, 9). In patients with 
severe cardiovascular disease, Cisatracurium with a dose 
of 6Xed95 (the effective dose required to produce 95% of 
muscle twitch response) or 0.3mg/kg had no effects on 
mean arterial blood pressure (10, 11). Since Cisatracuri-
um does not increase the plasma histamine level to more 
than 8x ED95, therefore, side effects resulting from ele-
vated plasma histamine concentration will not be seen 
in the patients with cardiac disease (12). It seems that 
Cisatracurium compared to Atracurium is an advanta-
geous muscle relaxant for patients under coronary graft 
surgery as it causes less effect on hemodynamic indexes 
(13). The purpose of this randomized double-blind clin-
ical trial was to compare the hemodynamic changes of 
the two muscle relaxants, Atracurium and Cisatracuri-
um, used in patients with low function of left ventricle 
who were candidate for open heart surgery.
2. MATERIALS AND METHODS
The patients were randomly placed in either of two 
groups using the following inclusion and exclusion cri-
teria. First of all, the dose of the relaxants to be admin-
istered, Atracurium or Cisatracurium was identical for 
both groups. During the induction, the anesthetist gave 
the patient an IM injection of relaxant within one min-
ute time, without being aware of the type of relaxant. 
Therefore, both the person filling out the questionnaire 
and the anesthesiologist were blind to the type of muscle 
relaxant.
Inclusion criteria:
• Patients with a cardiac disease history for more 
than 18 years and an ejection fraction of 35% or 
less who are candidate to undergo an elective car-
diac surgery.
• Cardiac surgery using cardiopulmonary bypass.
Exclusion criteria:
• Ejection fraction before surgery more than 35%
• Urgent surgeries;
• Surgery without cardiopulmonary bypass;
• Atrial fibrillation;
• Atrioventricular blocks, degrees 2 and 3.
After obtaining a written consent to inclusion in the 
study, patients meeting the above criteria were randomly 
divided in two groups of Atracurium (30 patients) and 
Cisatrurium (30 patients). They were then admitted in 
the operating room in supine position and the prelim-
inary steps for a general anesthesia were taken. A pe-
ripheral IV was made using an angio-catheter no.16 or 
18. After a local anesthesia, the atrial line was secured 
through the left radial vein for continuous monitoring of 
systolic and diastolic blood pressure and mean arterial 
pressure. Monitoring the patients venous O2 saturation 
and electrocardiogram started immediately upon their 
reception in the operating room. The anesthesia was in-
clude using 5 μg/kg of fentanyl, 0.2 mg/kg of etomidate, 
and a muscle relaxant, either 0.5 mg/kg of Atracurium or 
0.2 mg/kg of Cisatracurium. Before induction, the systol-
ic and diastolic BP as well as mean arterial pressure were 
recorded in the questionnaire as the basic vital signs. The 
vital signs were also recorded on minute before tracheal 
intubation, one minute after intubation, before surgery 
incision, after surgery incision, after opening the ster-
num, before starting pumping, after pumping and before 
transfer to ICU. The anesthesia was administered by in-
fusion of anesthesia agent through perfusion pump or 
syringe pump ATOM-1235N, sufentanil (0.01 – 0.02 μg/
kg/min) as amnestic agent, and the same relaxant used 
in the induction stage (Cisatracurium 2.5 μg/kg/min or 
Atracurium 10 μg/kg/min). During the surgery, isoflu-
rane was used to have good level of anesthesia and stable 
hemodynamic. The patients were under controlled me-
chanical ventilation (CMV) with volume of 8-10 mm/kg 
and a respiratory rate 10-12/min with dragger anesthesia 
machine, and had mechanical ventilation with O2 100% 
during the study. In case of heart rate decrease to less 
than 45/min, 0.5-1 mg of IV atropine was administered, 
and in case of systolic pressure decrease to less than 80 
mmhg, ephedrine was used in alternative doses of 10 mg, 
and finally if necessary adrenaline or dopamine was in-
fused. If the heart rate increased to more than 100/min, 
0.5 mg/kg esmolol (beta blocker) was used for at must 
two times. In case of increase of systolic blood pressure 
to more than 140mmhg, the dose of nitroglycerin was 
increased to 3 μg/kg/min or sodium nitro-proside was 
used with a dose of 0.5-1 μg/kg/min. Administration of 
any vasodilator or vasoconstrictor was recorded in the 
questionnaire. The date were then analyzed with the 
SPSS 13 software. As it was necessary to consider and 
evaluate the changes of hemodynamic indexes during 
the nine phases of monitoring and the influence of time 
on them in both groups, the variance analysis or repeat-
ed measurement analysis of variance was used.
3. RESULTS
Comparing the patients of the two groups under study 
who had received Atracurium or Cisatracurium, there 
was no statistically meaningful difference between them 
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in regard with age, sex, height, smoking, addiction to 
narcotics, using drugs such as beta blockers, calcium 
blockers, ACE inhibitors, and ejection fraction (Table 1).
The groups didn’t show any statistically meaningful 
difference in basic hemodynamic indexes including sys-
tolic pressure, diastolic pressure, mean arterial pressure, 
and heart rate either (Table 2).
After recording the basic hemodynamic indexes and 
induction of general anesthesia, the hemodynamic in-
dexes were recorded again in the following stage: 1 min-
ute before tracheal intubation, 1 minute after intubation, 
before surgical incision, after surgical incision, after 
sternotomy, before connection the pump, after discon-
necting the pump, and before transferring the patients 
to ICU.
Considering Figure 1, the flow of changes in systolic 
pressure in patients receiving Cisatracurium is smooth-
er, and there is statistically meaningful difference be-
tween the two groups in this regard.(P-value =0.00)
According to Figure 2, the changes in diastolic pres-
sure in Cisatracurium group compared to Atracurium 
group had meaningful difference (P-value=0.00), in a 
way that the decrease in diastolic pressure before surgi-
cal incision and after disconnecting the pump was more 
in Atracurium group.
The changes in mean arterial pressure had no statisti-
cally significant difference in the groups (P-value = 0.05).
As seen in Figure 3, there was a significant difference 
between the groups in regard with the range of changes 
in heart rate (P-value = 0.01)
Using vasoconstrictive and inotropic drugs made no 
significant difference in the groups (P-value = 0.3).
p-value
Atracurium
(Standard devi-
ation)
Cisatracurium
(Standard devi-
ation)
Indicator
0.28 60(7.5) 58(10.3) Age
0.30 157.6(12.8) 159(12.2) Size
0.4 69.69(9) 67.84(7) Weight
0.43 22 26 Cigarette
0.83 1 5 Addiction
0.64 10 11 Hypertension
0.66 22 22 Beta blocker
0.58 21 15 Inhibitors ACE
0.53 9 12 Heart- failure
0.55 10 13 Diabetes
0.67 30 28 Ejection fraction
Table 1. Patients in both groups compared to baseline indicators
p-value Atracurium Cisatracurium The basic hemodynam-ic parameters
0.28 141 125 Systolic blood pressure
0.46 71 68 Diastolic blood pressure
0.13 93 86 Mean arterial pressure
0.52 80 77 Heart rate
Table 2. Comparison of baseline hemodynamic parameters in 
patients
 
Figure  1: Comparison of changes in systolic blood pressure between the two groups in nine steps 
1. Before induction  
2. One minute before intubation 
3. One minute after  intubation 
4. Before surgical 
5. After surgical 
6. After  Sternotomy 
7. Before the pump 
8. After removing the pump 
9. Before being transferred to the intensive care unit 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of changes in systolic blood pressure 
between the two groups in nine steps. 1. Before induction, 2. One 
minute before intubation, 3. One minute after intubation, 4. Before 
surgical, 5. After surgical, 6. After Sternotomy, 7. Before the pump, 
8. After removing the pump, 9. Before being transferred to the 
intensive care unit, 
 
Figur   2: Comparis n of changes in diastolic blood pressure between the two groups in nine steps 
1.   Before induction  
2. One minute before intubation 
3. One minute after  intubation 
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6. After  Sternotomy 
7. Before the pump 
8. After removing the pump 
9. Before being transferred to the intensive care unit 
 
 
 
 
 
 
Figure 2. Comparison of changes in diastolic blood pressure 
between the two groups in nine steps. 1. Befor  i duction, 2. One 
minute before intubation, 3. One minute after intubation, 4. Before 
surgical, 5. After surgical, 6. After Sternotomy, 7. Before the pump, 
8. After removing the pump, 9. Before being transferred to the 
intensive care unit, 
 
Figure 3: Compared changes in heart rate in both groups in nine steps 
1. Before induction  
2. One minute before intubation 
3. One minute after  intubation 
4. Before surgical 
5. After surgical 
6. After  Sternotomy 
7. Before the pump 
8. After removing the pump 
9. Before being transferred to the intensive care unit 
 
 
 
Figure 3. Compared changes in heart rate in both groups in nine 
st ps, 1. Before inducti n, 2. One minute before intubation, 3. One 
minute after intubation, 4. Before surgical, 5. After surgical, 6. After 
Sternotomy, 7. Before the pump, 8. After removing the pump, 9. 
Before being transferred to the intensive care unit, 
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4. CONCLUSIONS
Using muscle relaxant in anesthesia for tracheal in-
tubation and muscle paralysis during surgery has been 
proved, and in many surgery centers the most common-
ly used muscle relaxant in cardiac surgeries is “pancro-
nium” (14). The desirability of pancuronium and using 
large doses of narcotics in cardiac surgeries goes back to 
years ago. In this method, pancuronium is administered 
to avoid the decrease in heart rate which results from 
use of narcotics. Nowadays, with increase of tendency 
to methods which require early and on time removal of 
tracheal tube as well as the tachycardia resulting from 
pancuronium in the induction stage, there is less tenden-
cy for its use. (15) Furthermore, contrary to intermedi-
ate-acting non depolarizing muscle relaxants, infusion of 
pancronium will cause longer paralysis after long surger-
ies.
Administering maximum 6Xed95 of IV Cisatracu-
rium (equivalent to 0.3mg/kg) in patients with severe 
cardiovascular disease did not reveal undesired and sig-
nificant clinical effects on heart rate and mean arterial 
blood pressure (16). In a clinical trial carried out on 141 
patients volunteer for coronary graft surgery, Cisatracu-
rium was administered 2-8xED95 (equivalent to 0.1 – 
0.4 mg/kg)and there was no elevated plasma histamine 
concentration. In the same trial, significant changes in 
hemodynamic indexes including heart rate and mean ar-
terial blood pressure was not seen, either (17). Another 
clinical trial made on 100 coronary graft surgery patients 
to compare the hemodynamic effects of Atracurium and 
Cisatracurium, reported similar stable hemodynamic. In 
the aforesaid trial, the range of mean without consider-
ing the standard deviation of patients ejection fraction 
was 42/6-45/9%. The premedication with beta and calci-
um channel blocker are also effective on hemodynamic 
indexes (18), but in our study, the two groups didn’t show 
any difference in the frequency distribution of premedi-
cation with these drugs.
As it can be seen in the result of this study, the absence 
of a significant statistical difference between the two 
groups in regard with the changes in the mean arterial 
blood pressure (p = 0.5) was due to similarity of systolic 
and diastolic pressure ratio.
In this study, the maximum ejection fraction of all the 
patients was 35% and according to recorded result it 
seems that the hemodynamic indexes were more stable 
in Cisatracurium group.
• Conflict of interest: none declared.
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